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ABSTRACT
Background: Dicobalt edetate and hydroxocobalamin are widely used to treat hydrogen cyanide poi-
soning. However, comparative and quantitative efficacy data are lacking. Although post-exposure treat-
ment is typical, it may be possible to administer these antidotes before exposure to first attenders
entering a known site of cyanide release, as supplementary protection to their personal protect-
ive equipment.
Methods: We established an anaesthetised Gottingen minipig model of lethal bolus potassium cyan-
ide (KCN) injection to simulate high dose hydrogen cyanide inhalation. Doses were similar to human
lethal doses of KCN. Dicobalt edetate and hydroxocobalamin were administered shortly before KCN
and their effect on metabolic and cardiovascular variables and survival time were measured.
Results: Increases in arterial lactate were similar after 0.08 and 0.12mmol/kg KCN. KCN 0.08mmol/kg
was survived by 4/4 animals with moderate cardiovascular effects, while the 0.12mmol/kg dose was
lethal in 4/4 animals, with a mean time to euthanasia of 28.3 (SEM: 13.9) min. Administration of dicobalt
edetate (0.021mmol/kg, 8.6mg/kg) or hydroxocobalamin (0.054mmol/kg, 75mg/kg) at clinically licenced
doses had modest effect on lactate concentrations but increased survival after administration of KCN
0.12mmol/kg (survival: dicobalt edetate 4/4, hydroxocobalamin 2/4) but not 0.15mmol/kg (0/4 and 0/4,
respectively). In a subsequent larger study, doubling the dose of hydroxocobalamin (0.108mmol/kg,
150mg/kg) was associated with a modest but inconsistent increased survival after 0.15mmol/kg KCN
(survival: control 0/8, 75mg/kg 1/10, 150mg/kg 3/10) likely due to variable pharmacokinetics.
Conclusions: In this porcine study of cyanide exposure, with pre-exposure antidote administration,
licenced doses of dicobalt edetate and hydroxocobalamin were effective at just lethal doses but inef-
fective at less than twice the estimated LD50. The efficacy of a rapidly-administered double-dose of
hydroxocobalamin was limited by variable pharmacokinetics. In clinical poisoning scenarios, with
delayed administration, the antidotes are likely to be even less effective. New antidotes are required
for treatment of cyanide exposures appreciably above the minimum lethal dose.
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Introduction
Hydrogen cyanide and cyanide salts are highly toxic industrial
chemicals that may be used in terrorist attacks [1–3]. Dicobalt
edetate and hydroxocobalamin are two established and
widely used antidotes [4–10]. Dicobalt edetate is the licenced
UK antidote and has been used since Paulet’s work on cyan-
ide antidotes in the 1950s [11]. Hydroxocobalamin has been
introduced more recently [6]. Few data are available on their
comparative efficacy and no randomised controlled trials have
been performed in humans. Analysis of their binding capacity
suggests that they bind only modest quantities of cyanide
(Box 1); however, it is possible that small reductions in free
cyanide concentration may be clinically beneficial.
Dicobalt edetate is associated with hypertension, tachycar-
dia, and retrosternal pain [10], while hydroxocobalamin is
associated with few adverse effects [7]. It may, therefore, be
possible to rapidly administer hydroxocobalamin to hazard-
ous area response teams (HART) first attenders before they
enter a site after known cyanide release, as a back-up for
their personal protective equipment.
However, a little-discussed problem with hydroxocobala-
min is its marked pharmacokinetic (PK) variation observed
after intravenous (IV) administration. In a dog study
(N106342) used for licencing, the Cmax could not be calcu-
lated due to the high degree of variation [12] (Table, p15). In
a porcine study of IV administration [13], Cmax varied 2.7-fold
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between animals (Eddleston et al. unpublished). Marked vari-
ation has also been seen in human PK studies, with Cmax
varying from 359 to 1360mg/L (mean: 813mg/L) in one
study of nine individuals [14] and from 288 to 995mg/L in a
licencing study reported to the European Medicines Agency
[12]. The clinical consequences of this PK variation are not
yet clear.
Box 1 . Chelation capacity of the two antidotes.
 The initial dose of hydroxocobalamin HCl (molecular weight ¼
1382) used in this study was 75mg/kg, or 0.054mmol/kg.
Hydroxocobalamin binds cyanide in a 1:1 molar ratio.
 Dicobalt edetate administered at 8.6mg/kg equates to
0.021mmol/kg (assuming that the given weight in the formulated
product refers to the anhydrous formula weight of 406). Dicobalt
edetate binds cyanide in a 1:2 molar ratio under physiological
conditions [45].
 If the administered quantities were fully available to react with cyan-
ide, a maximum of 0.054mmol/kg of KCN could be detoxified by
hydroxocobalamin and 0.042mmol/kg by dicobalt edetate. Double
the dose of hydroxocobalamin would detoxify 0.108mmol/kg.
 In the single bolus dose model reported here, the minimum lethal
dose for KCN was estimated to be between 0.08mmol/kg (100%
survival to 90min) and 0.12mmol/kg (100% lethal at 90min).
 The theoretical maximum cyanide binding capacity of the recom-
mended human doses of these antidotes is approximately half of
the minimum lethal dose for the animals in this model. The dou-
ble hydroxocobalamin dose is approximately equal to the min-
imum lethal dose.
Trials to assess the efficacy of antidotes for cyanide expos-
ure cannot be done in humans; studies have therefore been
done in animals including rodents [15], rabbits [16], dogs
[17], and pigs [18,19]. Porcine models of KCN poisoning are
probably most clinically relevant because pigs are relatively
close to humans in terms of physiology and metabolism [20]
and are widely used for toxicology studies [21].
Published large animal antidote studies have commonly
involved infusion of cyanide salts until a pre-defined end-
point (such as a 50% reduction in mean arterial pressure
(MAP), apnoea or cardiac arrest) was reached [18,22–24]. At
this point, the infusion was stopped, an antidote adminis-
tered, and effects on cardiorespiratory responses compared.
While these models are useful for proof of concept, they are
sensitive and able to detect very small improvements in effi-
cacy because the dose of cyanide received approximates the
minimum dose likely to be fatal. A small antidotal effect may
be protective at this dose, while providing little efficacy for
higher doses. The models do not assess treatment of toxicity
from an acute (bolus) exposure, as will occur in an attack, or
compare the efficacy between antidotes at different esti-
mated doses.
We established a pig model of KCN poisoning that could
be used to compare the efficacy of the two antidotes. We
used bolus intravenous doses of KCN to more closely simu-
late a sudden highly toxic exposure by inhalation. We gave
the antidotes immediately before exposure to maximise the
antidotes’ plasma concentrations at the time of poisoning
and test the possibility for prophylactic use. The KCN doses
used (starting at 5.25mg/kg) were modestly higher than the
estimated lethal dose in humans (150–300mg; 2–4mg/kg in
a 75 kg adult) [25], perhaps due to species differences or the
use of ventilation in the model. By doing so, we aimed to
establish the maximum protective benefit that these anti-
dotes can give at the doses chosen.
Methods
Animals
Experiments involved male G€ottingen minipigs (n¼ 64,
Ellegaard Minipigs ApS, Dalmose, Denmark) with mean weight
13.7 (SEM: 0.2) kg. Animals were barrier bred, shown to be free
of infections before shipment, and treated in accordance with
the Animals (Scientific Procedures) Act of 1986. The study was
performed under Home Office Licence after institutional eth-
ics review.
Cyanide and drugs
All compounds were obtained from Sigma-Aldrich, UK, unless
otherwise indicated. KCN and NaCN solutions were prepared
in phosphate buffered saline (pH: 7.4–7.5) 1–2 days before the
study and stored in stoppered syringes at 4 C. Injection vol-
umes in the range 5–9mL were adjusted to give the required
dose (mmol/kg) based on the animal’s weight on the day of
the experiment. KCl (Martindale Pharmaceuticals, UK) 15% (w/
v) solution was diluted with normal saline to give the required
dose in 10mL.
Hydroxocobalamin hydrochloride was dissolved in normal
saline to produce a 33.3mg/mL solution immediately before
use. Dicobalt edetate (Alliance Pharmaceuticals, UK) was
obtained as a 15mg/mL injectable solution. Volumes were
calculated to give the required doses based on the animal’s
weight on the experiment day.
Study design
Drug-naive animals were kept in pens and acclimatised under
the care of institutional veterinary surgeons before the study
as per the study laboratory protocol. Animals were fed a
standard diet but fasted overnight preceding the study; water
was available freely. Animals were weighed on the morning of
the study.
The experiment was conducted in phases, with the first
phase being used to identify approximate maximum surviv-
able and minimal lethal (MLD) doses of KCN that required
poisoned pigs to be euthanized within a target time of
90min. Based on the KCN dose used to cause cardiac arrest in
a previous pig study of hydroxocobalamin [23] and our own
pilot studies (unpublished), doses of 5.25mg/kg (0.08mmol/kg)
and 7.5mg/kg (0.12mmol/kg) of KCN were selected for initial
evaluation as a survivable dose and approximate MLD,
respectively. These doses were significantly higher than the
KCN doses used to induce apnoea in pig studies (1–2mg/kg)
[22,23]. In subsequent phases, antidotes were administered
immediately before cyanide at the MLD and then against a
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33% higher cyanide dose 10mg/kg KCN (0.15mmol/kg).
Before the highest dose was evaluated, we investigated
whether the potassium in the KCN could itself be causing a
toxic effect. Equimolar KCl and NaCN were administered in
the same manner as KCN, and the responses compared over
a shorter 30min period.
To reduce bias, animals were allocated to treatment
groups using a random number list; allocation could not be
predicted before randomisation.
Anaesthesia and instrumentation
The first study began each day at around 08:00 and up to
four studies were performed in one day. The methods of
anaesthesia induction, central vascular access, and instrumen-
tation together with continual cardiovascular monitoring of
animals have been described previously [13,26]. Preanesthetic
medication was intramuscular midazolam (0.5mg/kg) and
ketamine (5mg/kg). When profoundly sedated, the animals
were anaesthetised with 5% isoflurane in oxygen delivered
by facemask and intubated by direct laryngoscopy after local
anaesthesia to the hypopharynx with lidocaine 2% by a muco-
sal atomiser device. Anaesthesia was maintained to a clinically
acceptable depth with isoflurane in oxygen delivered by a cir-
cle breathing system.
Experimental protocol
Administration of KCN
After a 30min stabilisation period, KCN solution was given
by bolus injection over 40 s via a central venous line. The
volume of KCN solution administered was always 0.5mL/kg;
for example, the concentration for the starting dose of
5.25mg/kg (0.08mmol/kg) was 10.5mg/mL (0.16mmol/mL)
of KCN. This concentration was increased for higher doses to
ensure that the same volume was given in all studies.
Evaluation of antidotes
Antidotes were administered shortly before the KCN chal-
lenge at t¼ 0min. Hydroxocobalamin was given from
-10min until 0min; dicobalt edetate was administered from
-10min until -5min (followed by 1mL/kg of 50% glucose
from -5min to 0min as recommended by the manufacturer
[27]). The UK licenced dose of hydroxocobalamin is 5 g
(71.4mg/kg in a 70 kg adult) over 15min, repeated as neces-
sary over 15–20min [28]; we administered 75mg/kg or
150mg/kg of the hydrochloride salt by infusion over 10min.
The UK licenced dose of dicobalt edetate is 300mg over
1min (4.3mg/kg in a 70 kg adult) followed immediately by
50mL of 50% intravenous glucose solution, repeated as
necessary within 5min [28]. Because two doses could be
given rapidly over a few minutes, we combined both doses
and administered 8.6mg/kg as an infusion over 5min. In the
final study, comparing hydroxocobalamin 75mg/kg and
150mg/kg, the antidote was given earlier, from -30 to
-20min to ensure effective distribution to the tissue before
administration of cyanide.
Administration of NaCN and KCl
To determine whether potassium from the KCN solution con-
tributed to the toxicity seen with the 0.15mmol/kg KCN chal-
lenge, equimolar quantities of KCl (0.5mL/kg of a 23mg/mL
solution) and NaCN (0.5mL/kg of a 15mg/mL solution) were
each administered to groups of four pigs.
Blood sampling
Blood samples were taken at -30 and -10min prior to administra-
tion of cyanide or KCl, then at 5min and 10min post challenge.
Sampling continued at 10min intervals for up to 90min or until
euthanasia. A 0.2mL sample taken from the arterial catheter was
used immediately for blood gas and lactate analyses on an
EPOC blood analyser (Woodley Equipment Company Ltd, UK). It
was not possible to measure arterial oxygen tensions in groups
receiving high dose cyanide salts because of an interaction with
the blood analyser. At the same time, 5mL of blood was taken
from the central venous catheter; 2mL was frozen at -20 C as
whole blood for subsequent cyanide assay. The remaining sam-
ple was transferred to an EDTA-containing tube, centrifuged for
7min at 3900 rpm, and the plasma component stored frozen.
Euthanasia
The animals were given a fatal overdose of IV sodium pento-
barbital at the end of the study whilst under isoflurane
anaesthesia or when there was cardiovascular decompensa-
tion that did not show improvement in less than 10min
towards a MAP of >45mmHg.
Assays
Detailed methodology is given in the Supplementary
Appendix. Briefly, plasma hydroxocobalamin and cyanocobala-
min concentrations were analysed using an HPLC method
based on the work of Astier and Baud [29], and Chassaigne
and Lobinski [30]. Cyanide was measured in whole blood using
liquid chromatography-electrospray ionisation mass spectrom-
etry (LC-ESI-MS) based on the work of Tracqui [31] and Lacroix
[32]. Dicobalt edetate was measured as total cobalt in whole
blood using inductively coupled plasma-mass spectrometry
(ICP-MS) with collision cell technology and 7.5% (v/v) hydrogen
in helium as the collision gas [33].
Outcomes
The main study outcome for all but the last study was arterial
blood lactate concentrations. Secondary outcomes included
cardiovascular effects, time to euthanasia, and case fatality.
Case fatality was the primary outcome for the final study.
Statistical analysis
In the absence of previous data from this model, we did not
perform a power calculation for the initial studies and used four
animals in each group. However, to compare the hydroxocoba-
lamin high dose against a lower dose and placebo, using
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mortality as an outcome, a power calculation indicated that
group of 10 animals would allow detection of a treatment dif-
ference of 100% mortality in the control group and 30% mortal-
ity in a treatment group with 95% confidence and 80% power.
Primary data analysis was done in Prism 7 (GraphPad, San
Diego, CA). All animals were included in the analysis. Pig
weights plus clinical and biochemical outcomes were summar-
ised with mean and SEM. Comparisons between groups were
performed using t-tests. Statistical significance was assessed at
p< .05. All p values represent 2-tailed calculations.
Role of the funding source
The funders had no role in study design, data collection,
data analysis, data interpretation or writing of the report. All
authors had full access to all the study data and agreed with
the decision to submit for publication.
Results
Identification of approximate maximum survivable and
minimal lethal KCN doses
All four animals administered 0.08mmol/kg KCN survived to
the planned study duration of 90min. Three of four showed an
initial fall in MAP and pulse; all then showed hypertension and
tachycardia (Figure 1(A)). These effects settled over
about 70min.
Arterial lactate peaked at a mean of 15.8 (SEM: 1.4) mmol/L
at 40min compared to a baseline of 2.7 (SEM: 0.58) mmol/L;
p< .001; Figure 1(B)). It then fell modestly to a mean of 13.3
(SEM: 1.6) mmol/L by 90min (p> .05 compared to 40min).
All four animals that received 0.12mmol/kg KCN required
euthanasia due to sudden cardiac decompensation (Figure
1(A)) before 90min (mean survival time: 28.3min; Figure 2(A)).
Arterial lactate concentrations rose at a similar rate to that fol-
lowing the 0.08mmol/kg dose (maximum: 19.5mmol/L at
60min in the one animal that survived to this time; Figure
1(B)). Measured peak blood cyanide (CN, molecular weight
26) concentrations of 328.8 and 352.1lM occurred at the first
time point, 5min after KCN administration, in groups treated
with 0.08 and 0.12mmol/kg KCN, respectively (Table 1).
These two KCN doses were then taken as estimates of the
maximum survivable dose and MLD, as it was considered
unnecessary and unethical to study further animals to refine
further these estimates.
Evaluation of antidotes against an approximate
minimal lethal cyanide dose
Both antidotes showed efficacy when tested against 0.12
mmol/kg KCN. Four of four animals and 2/4 animals survived
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Figure 1. Cardiovascular and metabolic responses to cyanide with or without antidotes. (A) Cardiovascular (heart rate, MAP; 5min intervals) and (B) metabolic
(arterial lactate) responses to 0.08mmol/kg KCN (circle) and 0.12mmol/kg KCN (square) and to 0.12mmol/kg KCN following pre-treatment with hydroxocobalamin
(diamond) or dicobalt edetate (triangle). Values are mean ± SEM (for cardiovascular variables, of normalised responses [mean of -30min and -10min pre-cyanide
exposure values ¼ 100%]).
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to 90min after dicobalt edetate or hydroxocobalamin,
respectively (Figure 2(A)). Two hydroxocobalamin treated ani-
mals survived to 31min and 74min post-KCN exposure.
Despite improved survival, the antidotes only modestly
reduced the peak arterial lactate concentration (hydroxocoba-
lamin: 14.2mmol/L at 35min, dicobalt edetate: 13.3mmol/L
at 25min; Figure 1(B)) compared to no antidote (19.5mmol/L
at 60min) and had little effect on cardiovascular toxicity
(Figure 1(A)).
Neither antidote reduced peak cyanide concentrations fol-
lowing the 0.12mmol/kg challenge (Table 1). Mean peak
measured total cobalamin concentration (904mg/L) occurred
5min post-KCN exposure in the group given 0.12mmol/kg of
KCN (Figure 3(A)). Most of the cobalamin was in the cyano-
cobalamin form at 5min (79%) indicating that the rate of
combination of hydroxocobalamin with cyanide (and conver-
sion to cyanocobalamin) was unlikely to have limited its effi-
cacy. There was 2.4-fold variation in measured Cmax at 5min
for hydroxocobalamin between animals and 1.9-fold variation
in Cmax for cyanocobalamin.
The dicobalt edetate (measured as cobalt) concentration
was 6.8mg/L in animals 5min after administration of
0.12mmol/kg KCN (Figure 3(B)). The mean cobalt half-life
was 157.5 (SEM: 17.1) min, indicating that clearance should
not greatly reduce the efficacy of dicobalt edetate in
this experiment.
Exclusion of potassium toxicity
Before proceeding to evaluate the antidotes against a higher
KCN dose (0.15mmol/kg), we examined whether toxicity was
due in part to potassium, since potassium toxicity would
reduce apparent cyanide antidote efficacy.
Equimolar (0.15mmol/kg) KCl and NaCN were given by IV
administration over 40 s. KCl had no effect on cardiovascular
function or arterial lactate concentration (1.6mmol/L at 30min
compared to 1.9mmol/L pre-treatment, p¼ .185) (Figure
4(A–C)). All animals were well at the time of euthanasia,
30min post exposure (Figure 2(B)). In contrast, animals treated
with 0.15mmol/kg of KCN or NaCN showed similar rapid
changes in cardiovascular function associated with rising lac-
tate concentrations (Figure 4(A–C)). After 5min, mean lactate
concentrations had risen significantly to 7.9 [SEM: 0.44] mmol/
L with KCN and 6.8 [SEM: 0.45] mmol/l with NaCN [both
p< .001 compared to pre-exposure]; there was no difference
between CN groups, p¼ .130).
The measured peak blood cyanide concentrations at
5min were 682.5 and 684.7mol/L in the groups receiving
0.15mmol/kg KCN and NaCN. Mean times of euthanasia
were similar between groups: 7min for KCN and 8min for
NaCN (p¼ .33, Figure 2(B)). These results indicate that the
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Figure 2. Survival post cyanide dosing. (A) Survival following exposure to 0.08
or to 0.12mmol/kg KCN with or without antidotes. (B) Survival following expos-
ure to 0.15mmol/kg KCN, with or without antidotes, or equimolar KCl or NaCN.
The studies had planned maximum durations of (A) 90min and (B) 30min. All
animals that underwent euthanasia at this time had good cardiovascular func-
tion and were judged to have survived the procedure. Mean (SEM) time to
euthanasia are shown for each group.
Table 1. Free cyanide concentrations following administration of 0.08, 0.12 and 0.15mmol/kg KCN, and 0.15mmol/kg NaCN.
Cyanide salt:
KCN
NaCN
Dose (mmol/kg): 0.08
0.12 0.15
0.15
Antidote: None None HOCb DiCE None HOCb DiCE None
Time (min)
30 0 0 0 0 0 0 0 0
5 328.8 (17.1) 352.1 (34.9) ND 348.3 (37.8) 682.5 (50.6) 388.6 (20.3) 509.1 (29.1) 684.7 (66.2)
10 309.0 (53.0) 315.8 (13.0) 272.9 (27.6) 262.8 (21.0)
Hydroxocobalamin (HOCb, 75mg/kg) and dicobalt edetate (DiCE) were evaluated against 0.12 and 0.15mmol/kg KCN challenges. Values are mean (SEM) blood cyanide
concentrations (mmol/L CN). Values marked with an asterisk are significantly different (p< .05) from the equimolar cyanide challenge without antidote. ND: not done.
CLINICAL TOXICOLOGY 5
toxicity seen with KCN in this model is due to cyanide and
not potassium.
Evaluation of antidotes against the higher cyanide dose
Treatment with either hydroxocobalamin or dicobalt edetate had
no protective effect against the toxicity of 0.15mmol/kg KCN. All
animals showed a rapid rise in arterial lactate concentrations
(Figure 4(F)) at 5min post CN exposure to 7.9 (SEM: 0.44) mmol/
L (controls), 6.4 (0.43) mmol/L (hydroxocobalamin), and 7.1 (0.60)
mmol/L (dicobalt edetate; all p< .001 vs. pre-treatment values).
The between-treatment differences at 5min were not significant
(p¼ .051 and 0.338, comparing controls with hydroxocobalamin
and dicobalt edetate, respectively). MAP declined rapidly in all
animals (Figure 4(E)), with similar mean survival times of around
7min in control and treatment groups (Figure 2, p¼ .8 for com-
parisons of both treatment groups with control).
Compared to no antidote (peak mean cyanide concentra-
tion: 682.5mol/L), both hydroxo-cobalamin and dicobalt ede-
tate reduced cyanide concentrations at 5min post exposure
to 0.15mmol/kg KCN (388.6mol/L [p¼ .002 vs. control] and
509.1mol/L [p¼ .022], respectively; Table 1). However, the
observed cyanide concentrations were still higher than those
seen after 0.12mmol/kg KCN challenge and the antidotes
did not prevent a rise in lactate concentrations (Figure 4(F))
or delay death (Figure 2(B)).
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Figure 3. Pharmacokinetics of the antidotes. (A) Mean (SEM) blood hydroxocobalamin (orange diamond) and cyanocobalamin (red circle) concentrations after infu-
sion of hydroxocobalamin from -10 to 0min relative to a 0.12mmol/kg KCN challenge. The concentrations of hydroxocobalamin (triangle) and cyanocobalamin
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-10 to -5min relative to a 0.12mmol/kg KCN challenge. The cobalt concentration is also shown at baseline and at 5min after 0.15mmol/kg KCN ( square). Only a
5min sample was obtained following the higher KCN challenge due to all animals requiring euthanasia 6–9min post challenge.
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Figure 4. Effect of cyanide and potassium on cardiovascular function and lactate. (A–C) Cardiovascular (A: heart rate; B: MAP) and metabolic (C: arterial lactate)
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Peak total cobalamin concentration at 5min post-KCN
exposure was 780mg/L; again, most of the cobalamin was
in the cyanocobalamin form (97.0%, Figure 3(A)). A cobalt
concentration of 6.6mg/L was seen in the only sample
(5min) taken post-KCN exposure in the 0.15mmol/kg treat-
ment group (due to a rapid need for euthanasia).
Evaluation of a double hydroxocobalamin dose
We finally tested in a larger randomised controlled study
(n¼ 10 for antidote groups) whether rapid administration
of a double dose of hydroxocobalamin (150mg/kg, 10.5 g
for a 70 kg adult) given over 10min (from t¼30min to
t¼20min before cyanide) would substantially improve
efficacy compared to a standard 75mg/kg (5 g) dose
or placebo.
Control animals showed severe toxicity cardiovascular and
metabolic toxicity (Figure 5) after 0.15mmol/kg cyanide with
euthanasia being required at a mean of 10min post-expos-
ure in all eight animals (Figure 6). There was a modest dose
response in efficacy, with 75mg/kg causing 1/10 animals
to survive to 90min, whilst 150mg/kg caused 3/10 animals to
survive to 90min. There were no differences in the time to
euthanasia in animals requiring this intervention (control: 10.6
(SEM: 1.3) min, 75mg/kg arm: 13.2 (1.6) min, and 150mg/kg
arm: 11.7 (1.8) min). Surviving animals were hypotensive and
tachycardic throughout the study.
Measurement of blood cyanide and hydroxocobalamin
concentrations provided an explanation for the variation.
Mean peak blood cyanide concentrations were similar at
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5min: control: 470 (SEM: 37) mmol/L; 75mg/kg arm: 437 (29)
mmol/L; and 150mg/kg arm: 430 (35) mmol/L (Figure 7(A,D)).
However, plasma hydroxocobalamin (Figure 7(B,E)) and
cyanocobalamin (Figure 7(C,F)) concentrations showed
markedly variable pharmacokinetics at both doses (hydroxo-
cobalamin maximum 5.0 and 10.7-fold variation, and cyano-
cobalamin maximum 5.1 and 7.5-fold variation, for 75mg/kg
and 150mg/kg doses, respectively). Animals surviving the
cyanide challenge had substantially higher plasma hydroxo-
cobalamin and cyanocobalamin concentrations compared to
the other animals. There was a clear correlation between
antidote effectiveness and plasma cobalamin concentrations
(Figure 7).
Discussion
The use of chemical weapons in attacks on civilians has
increased markedly over the last decade, but there has been
little progress in the clinical development and use of novel
highly effective antidotes for treatment. The use of hydroxo-
cobalamin has been heavily promoted for treatment of cyan-
ide toxicity [6,8,9,34–36] but there is little comparative
evidence on efficacy. In this study of minipigs poisoned with
a rapid intravenous infusion of potassium cyanide, although
both hydroxocobalamin and dicobalt edetate showed some
efficacy at minimally toxic doses, neither were highly effect-
ive. Hydroxocobalamin – when given in double the licenced
dose and at eight times the recommended infusion rate
(equivalent human dose: 10 g over 10min) – was effective
for some animals at but not others. Its efficacy was limited
by the highly variable pharmacokinetics that have been pre-
viously noted.
Even this modest benefit is unlikely to occur in chemical
weapon attacks, when there is rapid inhalation of cyanide gas.
We gave the antidotes shortly before the cyanide to maximise
the chance of benefit. However, ventilated animals that did
not receive an antidote required euthanasia due
to cardiotoxicity within ten minutes of administration of a
relatively modest dose of cyanide (substantially less than 2
the LD50). Unless the antidotes can be given before or within
a few minutes of exposure, as done by the military with
oximes and atropine for OP nerve agent attacks [37], it seems
unlikely that they will save many lives. It might be possible to
infuse hydroxocobalamin as additional protection into first res-
ponders entering a scene with cyanide released but, even in
this prophylactic situation, protection would be modest.
Arterial lactate is used as a marker of high toxicity, with
concentrations greater than 10mmol/L associated with mod-
erate-severe toxicity [4]. However, in our model, the usually
sub-lethal 0.08mmol/kg (5.25mg/kg) dose produced similar
lactate rises to the lethal 0.12mmol/kg (7.5mg/kg) dose. In
addition, pre-treatment with effective doses of antidote at
the 0.12mmol/kg dose did not alter the rise in lactate con-
centration, suggesting that high arterial lactate concentra-
tions may not be a reliable biomarker of cyanide poisoning
and severity.
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Hydroxocobalamin was associated with no apparent
adverse effects, while the double dose of dicobalt edetate
caused marked hypertension that settled over 10–20min.
This adverse effect has been noted previously [10]. A drug
that causes hypertension might be beneficial to patients
with severe cyanide poisoning in whom hypotension is
expected. However, we saw no such beneficial effect in this
model. There are few data on dicobalt edetate pharmaco-
kinetics in humans or pigs. It likely distributes rapidly into
the extracellular fluid where it binds cyanide. Since it has a
long elimination half-life and was given just before the
cyanide dose, it is unlikely that rapid clearance was respon-
sible for its poor efficacy.
The modest efficacy of hydroxocobalamin was unex-
pected. The half-life of hydroxocobalamin following IV or
intraosseous administration in minipigs is 145min [13].
Therefore clearance is not responsible for its lack of efficacy.
Instead, it is more likely to be related to limited cyanide
binding capacity (Box 1) and poor ability to reduce circulat-
ing free cyanide concentrations to sub-toxic levels.
The difference with previous studies of hydroxocobalamin
that have reported efficacy may be due in part to the differ-
ent peak blood cyanide concentrations in the models. Peak
concentrations in this ventilated model (685lM [17.8mcg/
mL] for a dose of 0.15mmol/kg NaCN) were substantially
higher than reported from others models, ranging for
example from 64.5 lM (1.68mg/L) [22] to 130.6lM (3.4mg/L)
[38]. However, the pig results are consistent with blood con-
centrations measured after lethal cyanide poisoning in
humans (150–1700lM) [39]. Pigs with a mean blood concen-
tration of 329 mmol/L, after 0.08mmol/kg, survived without
antidotes. Of note, animals euthanised after 0.12mmol/kg
had only slightly higher blood cyanide concentrations; how-
ever, the small numbers preclude detailed assessment of
plasma CN concentrations associated with mortality.
The dose of cyanide found to be survivable in this study
(0.08mmol/kg, 5.25mg/kg) was higher than uniformly fatal
doses in other studies eg. 4.91 (SD: 1.3) mg/kg in the study
of Bebarta et al. [23]. The duration of dose administration
(40 s vs. 25min) in the two studies is likely to be the cause
for the difference in the lethal dose (as well as in time to
death and lactate concentration), perhaps with a contribu-
tion from differences in pig strain (in-bred Gottingen vs. out-
bred Yorkshire). The approximate lethal dose in our studies
of 400–500mg for a 75 kg adult was about 2-fold higher
than the literature’s estimate of 200–300mg, likely due to
differences between the model and human poisoning.
Peak blood cyanide concentration in the low dose group
which survived was 328mol/L (8.5mg/L). This is significantly
higher than published human concentrations, which suggest
that concentrations >3mg/L are lethal [40]. However, the
peak concentration was measured only five min after rapid
dosing. In clinical practice, blood is rarely taken for cyanide
measurement so soon after exposure, nor is it (usually) taken
from a live patient as occurred with these animals. The blood
concentrations in this study were therefore expected to be
significantly higher than those measured in clinical cases,
many of which were post-mortem.
Hydroxocobalamin was registered with the European
Medicines Agency on the basis of a clinical dossier compris-
ing one safety study and four non-comparative efficacy
studies (one prospective, three retrospective) [12]. None of
these human studies can confirm effectiveness. To over-
come this lack of data, a placebo-controlled canine study
was performed. This study involved infusing KCN until the
dogs had been apnoeic for three minutes (mean total dose:
2.2–2.4mg/kg), whereupon the cyanide was stopped and
animals administered placebo, or hydroxocobalamin 75 or
150mg/kg [17]. In this “precipice” model (see introduction),
both doses of hydroxocobalamin were effective.
We initially tested the UK’s licenced adult dose of hydrox-
ocobalamin 5 g (71.4mg/kg in a 70 kg adult), 0.054mmol/kg
assuming a molecular weight of 1382 for hydroxocobalamin
HCl. If this total amount is available to react with CN soon
after administration, an equivalent molar quantity of CN
could be bound (Box 1). These simple calculations suggest
that, at best, the licenced dose of hydroxocobalamin can
bind around half a minimum lethal dose (about 0.06mmol/
kg of KCN) and the double dose should be able to bind a
just lethal dose.
Although there are some concerns about the effective-
ness of hydroxocobalamin for smoke cyanide toxicity [41],
its administration to self-ventilating patients extricated
from house fires with presumed cyanide toxicity is widely
recommended [6,8,42,43]. Our study suggests that patients
with cyanide exposure as indicated by high lactate concen-
trations who have stable cardio-vascular function may
survive without antidotes, and that antidotes only offer
limited additional protection. In the absence of controlled
clinical trials, the available evidence does not support rou-
tine administration of the cyanide antidotes to unconscious
patients exposed to house fires [41]. A cluster RCT compar-
ing the administration of hydroxocobalamin by ambulance
paramedics to unconscious patients at the scene of the
exposure with an equivalent amount of 0.9% sodium chlor-
ide solution would provide the data required to determine
whether this approach is effective.
Limitations
The study was carried out in pigs because well controlled
human studies are not possible. However, porcine cardio-
respiratory physiology is similar to humans [20] and human
equivalent doses of antidotes were given. We performed
an initially small focussed study that was not powered to
distinguish small differences in time to death following
treatment with different antidotes. We finally compared
hydroxocobalamin in a larger study that was powered to
detect substantial differences in mortality, but this did not
show reliable efficacy.
In order to optimise cardiovascular stability and reduce
both variability and number of animals required, the study
was performed in anaesthetized pigs in which tracheal intub-
ation and positive pressure lung ventilation were imposed.
The time to apnoea was therefore not recorded. This does
not match the real-life situation in which patients would not
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be intubated or ventilated. An ability to prevent respiratory
arrest in a self-ventilating patient at lower cyanide doses
might increase the benefit from cyanide antidotes. However,
this would again require early treatment.
Due to a local lack of inhalational facilities to perform
hydrogen cyanide studies in anaesthetized and ventilated
pigs, we chose to give bolus doses of KCN to simulate sud-
den massive cyanide inhalation. This situation differs from
that following ingestion of cyanide salts in which death
would be expected to occur later.
The study also looked at mortality but not long-term seque-
lae; it is possible (but perhaps unlikely) that both antidotes are
highly effective at reducing such sequelae while only moder-
ately reducing death.
Conclusion
In these porcine studies, we found modest beneficial effects
from double doses of hydroxocobalamin or dicobalt edetate
given immediately before a just lethal exposure to cyanide.
Increased doses may improve effectiveness but have not
been tested either pre-clinically or clinically. More effective
antidotes are urgently required. Candidates include cobina-
mide, an analogue of hydroxocobalamin with twice the
molar cyanide binding capacity [15,22], and sulfanegen, a
dimeric prodrug of 3-mercaptopyruvate that is a substrate
for the cyanide-detoxifying enzyme 3-mercaptopyruvate sul-
furtransferase [15,24]. Recently, a liposomal construct con-
taining rhodanase and a novel sulphur donor has been
reported to increase the LD50 of KCN 15-fold when given
prophylactically to mice [44], a far higher level of protection
than given by the antidotes discussed here.
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